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Essentials
• The risk of recurrent venous thrombosis (VT) after legcast in patients with prior VT is unknown.
• In a nested case-control study within the MEGA follow-up study we aimed to estimate this risk.
• Patients with a history of VT who require lower-leg cast have a 4.5-fold risk for recurrence.
• This relative risk translates to an absolute risk for recurrent VT of about 3.2% within 3 months.
Summary. Background: Patients with lower-leg cast immobilization have a substantially increased risk of developing a first venous thrombosis (VT), whereas the risk in patients with a history of VT is as yet unknown. Aims: To estimate the risk of recurrent VT after lower-leg cast immobilization in patients with a history of VT. Methods: A case-control study nested within a cohort of 4597 patients with a first VT who were followed over time for recurrence from 1999 to 2010 (MEGA follow-up study). Participants completed a questionnaire on risk factors for recurrent thrombosis, including having a cast in the first 3 months before a recurrence (cases) or a random 3-month period during followup for participants without recurrence (controls). In total, 2723/4597 (59%) participants returned the questionnaire. Odds ratios (ORs), adjusted for age and sex, were calculated to compare risks of recurrence between subjects with and without a cast. [1, 2] . However, the risk of developing a recurrent VT following cast immobilization in patients with a history of VT is as yet unknown. Knowledge on this risk can further support clinical policy regarding thromboprophylaxis treatment in these patients. Unfortunately, almost all large trials on this topic excluded patients with a history of VT, so that precise risk estimations cannot be made [3] [4] [5] [6] [7] [8] .
To date, multiple studies have focused on the prediction of recurrent VT (for both unprovoked and provoked recurrent events) by using risk factors that are present during the first thrombotic event. Yet, these risk assessment models lack discriminative ability, which is not surprising because prediction of a provoked recurrent event is challenging [9] . For optimal prophylactic strategies, identifying the risk of recurrence around periods with an increased thrombosis potential (such as cast immobilization) is crucial for the prevention of a provoked recurrent event. In this study we aimed to estimate the risk of a recurrent VT shortly after lower-leg cast immobilization in patients with a history of VT.
Methods

Study population
We used data from the Multiple Environmental and Genetic Assessment follow-up study (MEGA-follow-up study). Details have been published previously [10] . In short, the MEGA study is a population-based case-control study of the etiology of VT. A total of 4956 consecutive patients with a first DVT, PE or both were recruited from six anticoagulation clinics in the Netherlands between 1999 and 2004. The diagnosis was confirmed by (Doppler) ultrasonography, ventilation-perfusion scan, angiography or spiral CT scan. Control subjects were either partners of cases or recruited via random digit dialing [11] .
Details of the MEGA follow-up study were also published previously [10] . A total of 4731 cases from the MEGA case-control study agreed to participate in the follow-up study. Patients were followed over time to determine incidence rates for recurrent VT Recurrences were classified into certain and uncertain recurrences (depending on information obtained from questionnaires, hospital discharge letters, anticoagulation clinics and death certificates). For this analysis only certain recurrences were used. In addition, the MEGA follow-up database was linked to The Dutch Foundation for Pharmaceutical Statistics database, which provides information on all medical prescriptions from 95% of all public pharmacies in the Netherlands [12] . The MEGA follow-up study was approved by the Medical Ethics Committee of the Leiden University Medical Center and all participants gave informed consent.
Data collection
In addition to the first short questionnaire on the occurrence of a recurrent event, participants were asked to complete a second questionnaire on putative risk factors for recurrent VT, asking for information on the period previous to the recurrent event or a random control period for participants who did not develop a recurrence. Application of a cast to the lower extremities was identified with the question: Did you have a cast within 3 months previous to your second VT? Cast location (e.g. type of leg cast, such as above or below the knee) and date were also recorded. For all analyses we considered the 3-month time window from cast application onwards. No other detailed information was available (e.g. weight bearing vs. non-weight bearing, circular or splint cast or surgical vs. non-surgical treatment). For those patients who did not develop a recurrence the same question was asked, only the reference date was a 3-month period before a random control date during follow-up.
Statistical analysis
We performed a nested case-control study within the MEGA follow-up study. Patients with an uncertain diagnosis of recurrence were excluded. Cases (patients with certain recurrent VT) and controls (those without a recurrent VT) were identified. Finally, cases and controls who did not complete the questionnaire, or for whom information on cast immobilization was missing, were also excluded from the analysis. (Fig. 1) .
To compare the risk of recurrence between subjects with and without cast immobilization (all locations) we estimated the relative risk (RR) by calculating the odds ratio (OR) with the 95% confidence interval (95% CI). In addition, an OR adj adjusted for age and sex was calculated using binary logistic regression. First, we calculated the OR for the development of recurrent VT for all types of cast immobilization. Subsequently, individuals with a cast in a location other than the lower leg, or with location missing, were excluded. Then we calculated the OR for recurrence for subjects with and without a lower-leg cast. Finally, after verifying the cast date and recurrence date in the patient's records (to check the 3-month window for application of a cast prior to a patient's VT or the control date), we recalculated the relative risk of recurrence (sensitivity analysis, Fig. 1 ).
Results/Discussion
Four hundred and fifty-one cases and 2074 controls were included in the analysis after exclusion for various reasons (Fig. 1) . The mean age of the study cohort was 47.7 years and 44.2% was male.
Fourteen of 451 subjects had any cast within 3 months prior to their recurrent VT (10 lower extremity, three another location and one with location missing) and so did 43/2074 controls (20 lower extremity, 16 another location and seven had location missing; 3 months prior to the control date), for an OR of 1.5 (95% CI, 0.8-2.8) (Table 1) . Subsequently, four cases and 23 controls were excluded because of cast location other than the lower extremities (i.e. arm, hand, finger and spine) or missing location, leaving subjects with or without cast of the lower extremities only (10 cases and 20 controls with lower-leg cast). These patients had a 2.3-fold increased risk of developing a recurrent VT (95% CI, 1.1-5.0), which hardly changed after adjustment for age and sex (OR adj , 2.4; 95% CI, 1.1-5.3) ( Table 1 ). The main reasons for cast immobilization were fracture (40%), distortion (40%) and Achilles tendon rupture (20%). As these risks were self-reported we cross-checked the recurrence date and cast date in the patients' medical records or discharge letter. By doing so, we were able to confirm cast of the lower leg within 3 months prior to the recurrent VT/control period in 6/448 cases and 7/2058 controls (median time to recurrence from cast application onwards was 14 days). In most other patients the cast date did not match the 3-month window before the recurrence date or the control period. Therefore, these patients did have a cast, but not within the specified time window. This further refinement resulted in a 4.0-fold increased risk of recurrent VT (95% CI, 1.3-11.9), adjusted for age and sex (OR adj , 4.5; 95% CI 1.5-14.0) ( Table 1) . A corresponding cumulative incidence of 3.2% at 3 months can be derived from these numbers: 28.1 recurrent VT cases per 1000 individuals per year (baseline) * 4.5 = 126.4/ 1000/year, corresponding to 126.4/1000/4 = 3.2% recurrent events within 3 months following lower-leg cast immobilization.
By reviewing discharge letters and medical records (pharmacy database) a prescription for anticoagulation medication could not be retrieved for most cases. The most likely explanation for this is that these prescriptions were issued at the hospital pharmacies, which are not included in the outpatient pharmacy database we used. *OR adj denotes adjusted odds ratio for age and sex; CI, confidence interval. †Confirmed lower-leg cast within a 3-month window from a patients' medical record.
Therefore, we cannot state for certain how many patients received prophylactic therapy. Our results might be limited by misclassification of the cast date (i.e. unintentionally misclassifying a case or a control as having [or not having] had a lower-leg cast within 3 months as a result of recall bias). In this case, the cases better remember possible exposure to cast immobilization than control patients, which could have led to an overestimation of the OR. On the other hand, a leg injury requiring a cast is a memorable event, so the effect of recall bias might be limited. To verify our results, we performed a sensitivity analysis, which showed that mainly controls had been misclassified (they did have a lower-leg cast, but not within the time period specified). This refinement led to a 4.5-fold increased risk of VT, reflecting the misclassification that had been present in the overall analysis. Furthermore, for 33 cases and 181 controls no information on cast application was present (out of all participants who filled out the questionnaire). However, as the proportion of patients with missing information was similar in cases (7.4%) and controls (8.0%), it is unlikely that missing information has led to biased results. In addition, all controls were sampled at the end of follow-up (thus no selection of controls) and not matched on follow-up duration with cases. Possibly, this approach may have led to an underestimation of the actual risk if controls who were lost to follow-up had died because of a lung embolism due to cast immobilization, although this is unlikely. As a final limitation, it is unknown whether all patients received thromboprophylaxis during cast immobilization. However, according to a recent survey study conducted in the Netherlands, thromboprophylactic therapy was prescribed for 79% and 63% of patients with cast immobilization of the lower leg by trauma surgeons and orthopedic surgeons, respectively, and if any risk factors were present (such as VT in a patient's history) for an additional 15% and 33% of patients, by trauma and orthopedic surgeons, respectively [13] . Therefore, it is likely that almost all patients with a history of VT received thromboprophylactic therapy during immobilization (according to most guidelines).
Recently, van Adrichem et al. reported that patients with cast immobilization of the lower leg have a 32-fold risk of developing a first VT within 3 months [1] . The lower risk that we found (4.5-fold increased) for recurrent VT after cast application might partly be explained by thromboprophylactic therapy, as patients with a history of VT have a high risk of developing a recurrence and therefore clinicians may be more willing to prescribe thromboprophylactic therapy than for a first event.
Another explanation for this lower risk is the high baseline risk of recurrent VT as compared with the baseline risk of a first VT, also known as the 'recurrence paradox' [14] . Suppose that in absolute terms, the baseline risk of a first VT is 1 per 1000 individuals per year, thus 0.25 per 3 months [15] . Considering a relative risk of 32, this leads to an absolute risk of VT following a lower-leg cast of about 8 per 1000 individuals within 3 months (thus 7.75 extra cases). Now, consider a population at risk of recurrent VT at an incidence rate of 30 per 1000 individuals per years, thus 7.5 per 3 months) [16] . The extra VT risk as a result of lower-leg cast immobilization would lead to 7.5 plus 7.75 = 15.25 cases per 1000 individuals within 3 months, thus a relative risk of 2.1 (15.25 divided by 7.5). Hence, the relative risk of recurrence is lower compared with the risk of a first VT after cast immobilization, because of the higher baseline risk.
For patients with a history of VT, most guidelines advise assessing VT and bleeding risk in circumstances of an increased risk (e.g. surgery, hospitalization, etc.). Patients with a personal history of VT are considered to be at high risk for the development of a recurrence during these situations. Therefore, all guidelines advise giving thromboprophylactic therapy in these situations, for example during cast immobilization [17, 18] . In our study, patients with a history of VT and a cast of the lower leg had a 4.5-fold increased risk, and corresponding cumulative incidence at 3 months of 3.2%. Based on this high risk, we carefully suggest that in these patients a prophylactic dosage might not be sufficient and therapeutic dosages should be considered on an individual patient basis. However, with the risk of bias and unknown information on thromboprophylaxis taken into account, our advice should be interpreted with caution. Also, an individual's bleeding risk has to be determined before such interventions can be applied. At any rate, thromboprophylaxis is strongly advised for patients with cast immobilization of the lower leg and a history of VT.
